Biology

#Benchling #Biology #Chemistry #Drug discovery #Webinar

Webinar: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

#News

#Biology #Clinical trials #Drug discovery #New approach methodologies (NAMs)

A turning point for human-based drug discovery 

Daniel Delubac, Chief Executive Officer at iOrganBio, looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models.  The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes of Health (NIH) announced a $150 million investment to support the development of novel approaches that mimic human biology to reduce… Read More

#Exclusive Content

Neuroscience Parkinson's disease
#Biology #Drug discovery #Neuroscience #Parkinson's

Parkinson’s disease and CDNF: Turning a neurotrophic factor into a viable therapy 

Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease.   Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. If a… Read More

#Exclusive Content

#Biology #Biotech #Canada

VoxCell appoints Graham Craig as COO 

Canadian biotechnology company VoxCell has appointed Graham Craig as Chief Commercial Officer (COO).  Craig joins VoxCell from clinical-stage biotechnology company AbCellera with experience in commercialisation and strategic partnerships across the pharmaceutical and biotech sectors. Craig will lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of… Read More

#News

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

#Biology #Cell and gene therapy #Cell therapy #Financing #Harvard Medical School #iPSC

Cell therapy company GC Therapeutics launches with $75m 

GC Therapeutics (GCTx) has launched with $75 million in total capital.  GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome (Transcription-Factor-ome), was invented and developed by scientists in the lab of Professor George Church at Harvard Medical School and the Wyss Institute.  It integrates synthetic biology, gene editing, cell engineering… Read More

#Business & Investment #News

#Biologics #Biology #Dewpoint Therapeutics #Partnership

Podcast: In conversation with Isaac Klein, CSO, Dewpoint Therapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Isaac Klein, Chief… Read More

#News

DNA
#Biology #Evonetix #Synthetic biology #Synthetic DNA #University of Cambridge

Desktop DNA synthesis could ‘revolutionise’ engineering biology

The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge. Read More

#News

Brussels, Belgium
#Biology #Events #Genomics #High Throughput #In vitro #Organ-on-a-chip #Organoids #SLAS #SLAS Europe

SLAS Europe 2023 reveals details of Biology Unveiled track

SLAS Europe has revealed details of the Biology Unveiled track at the upcoming meeting in Brussels, Belgium on May 23-26. The other three tracks are Frontiers in Technology, Shaping the Future of Therapeutics and Bio-Entrepreneurship in Europe. The Biology Unveiled track will feature scientific… Read More

#News

#Biologics #Biology #Biotechnology #Drug development #Therapeutics

Next-generation pipeline for treating mast cell driven diseases 

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies.  Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More

#News

#AI / data analytics / healthtech / informatics #Bioengineering #Biology #Lab automation #SLAS2023

Listen now: Connecting lab automation to decision-making

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March) DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode three, Connecting lab automation to decision-making. In this episode, we… Read More

#News

Protein degradation
#Biology #CRO #Drug development #Drug discovery #Genomics #Protein chemistry / Proteomics #Therapeutics

New podcast on CROs and targeted protein degradation

This is the latest episode of the free narrated DDW podcast, “CROs and targeted protein degradation offer an exciting future”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “CROs: Drug discovery expertise on hand” and “Why the emergence… Read More

#News

#Animal models #Biology #Drug discovery #MPS technology #Podcast

Podcast: The role of animals in the future of drug discovery

This is the latest episode of the free DDW podcast, “The role of animals in the future of drug discovery”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “How an animal model… Read More

#News

#Biology #Clinical trials #Diversity #Oncology

What it takes to make cancer research more inclusive

The drug discovery sector is working to address cancer disparities. Anita Ramanathan examines the importance of inclusivity and diversity throughout the drug discovery and development process.  While the risk of cancer is universal, some groups are disproportionately affected by cancer compared to others. Disparities resulting from genetic, environmental, social, and… Read More

#Cancer Research #Exclusive Content

#Biology #Genetics / genomics #Single-cell analysis #Webinar

Resolving complex biology with single cell and spatial multiomics

Single cell and spatial tools from 10 X Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. Resolving complex biology with single cell and spatial multiomics was presented by Stephen Hague, Managing… Read More

Webinar date:
Brought to you by 10 X Genomics
#Webinars

#Biology #Drug discovery #IBD

Galapagos advances IBD targets discovered using Scipher platform

Biotechnology company Galapagos will in-license drug targets for inflammatory bowel disease (IBD) which were discovered using a biology platform developed by Scipher Medicine. The move follows a deal Galapagos and Scipher Medicine made in 2020 to jointly validate a suite of novel IBD targets discovered by Scipher’s Spectra platform. Under… Read More

#News